STITCHES - the Best Papers in General Surgery’s Post

Ophthopedia Update:This Issue at a Glance: Tadayoni et al (p. 950) conducted 2 identically designed phase 3 trials evaluating the 24-week efficacy and safety of faricimab, a dual angiopoietin-2 and VEGF-A inhibitor, compared with aflibercept for treating macular edema resulting from either branch retinal vein occlusion (RVO) or from hemi-RVO and central RVO. Analysis of 553 patients with branch RVO and 729 patients with central or hemi-RVO found that the best corrected visual acuity gains from baseline to week 24 with faricimab were noninferior versus aflibercept. #Ophthalmology #ophthotwitter #eyecare

Comparison of bleeding and thrombotic outcomes in VV ECMO: Heparin versus bivalirudin https://lnkd.in/dVTwFQZ4 • In this study, thrombotic and haemorrhagic complications of heparin (n=61) and bivalirudin (n=34) use in VV ECMO were evaluated. • In the bivalirudin group; ○ Lower thrombotic events and higher membrane lifespan despite higher rates of severe COVID-19, higher BMI and longer ECMO duration, ○ Less blood and platelet replacement per 100 ECMO days, ○ Improved survival to ECMO decannulation in univariate analysis were found.

Check out this message from Yale Medicine about LIVER DISEASE and #MASH (Metabolic dysfunction-associated steatohepatitis, formerly known as #NASH). The clear explanation emphasizes how the accumulation of fat in the liver is a key factor that drives liver tissue damage, which could lead to fibrosis and cirrhosis. https://lnkd.in/gq_zGJdq Livivos, Inc is developing the #LiverScope to enable quantification of liver fat in point of care. See details www.livivos.com #liver #liverdisease #liverfat #inflammation #fattyliver #fibrosis #cirrhosis #pointofcare #resmetirom #liverdamage #Rezdiffra Madrigal Pharmaceuticals

BioCity published the results of a Phase I clinical study of a highly selective small molecule antagonist of the ETA receptor，the results of the Phase I clinical study showed that SC0062 demonstrated favorable safety, pharmacokinetic and pharmacodynamic profiles in healthy subjects, which lays a solid foundation for the current clinical trials in chronic kidney disease (CKD) with hyperproteinuria, such as IgA nephropathy and diabetic nephropathy (DKD), as well as the subsequent development of potential indications in other disease areas. https://lnkd.in/gJss64yU

The ELITE-Symphony study has influenced KDIGO guidelines for renal transplant immunosuppressive therapy, recommending induction therapy with tacrolimus, mycophenolate, and steroids. However, concerns about nephrotoxic effects and delayed graft function associated with tacrolimus blood levels persist, as evidenced by studies like the Symphony trial. A proposed hypothesis suggests early low and fixed tacrolimus dosing as a safer alternative, with a study underway to compare this approach with the standard method. Read more - https://lnkd.in/dFaShJwu #kidneytransplant #kidneyrejection #Tacrolimus #immunosuppressivetherapy #renaltransplant #KDIGO #ConcordBiotech

This is why IFC was recognized by the FDA as a breakthrough product. It saves time and prevents waste. IFC is the new standard of care for hemorrhaging patients being adopted by top hospitals. Questions? Let’s connect!

While fibrinogen is generally recognized as a critical blood clotting factor that can decline quickly in the massive hemorrhage patient, logistical challenges often prevent its rapid administration. Earlier this month, the American Journal of Clinical Pathology published the experience of Dr. Sethapati et al. with the implementation of pathogen reduced cryoprecipitated fibrinogen complex (commonly referred to as INTERCEPT Fibrinogen Complex) at Stanford Health Care’s Blood Bank. The publication, which details the positive impact of this blood product on waste and turnaround time at a single site, can be found here: https://ow.ly/HBIp50SAsrU #massivehemorrhage #transfusion #fibrinogen

Nephrology towards precision medicine through nucleic acid therapeutics! ERA G&K aims to learn how this changes the landscape of patient care in both PH1 and kidney medicine in general. We would like you to contribute and fill the survey (explicitly NOT only but also for PH1 experts): https://bit.ly/433iqVT

For all my #raredisease followers.. The FDA just approved #Winrevair (sotatercept-csrk) for #PAH. Winrevair was tested as an adjunct to established dual or triple PAH therapy. Most of its side effects were hematologic, including thrombocytopenia and increased haemoglobin. Current therapies for PAH include vasodilators, and treatments that address smooth muscle cell overgrowth, inflammation, and platelet aggregation. Unique from other current vasodilators approved for the condition, Winrevair appears to directly reduce MAP without increasing cardiac output. Winrevair is an activin signaling inhibitor. It is given SQ once every 3 weeks. Like prostacyclin therapy, Winrevair has reproductive impacts. For a crash course on the latest in PAH, check out this review: 10.3390/ijms24043332

Fecal transplantation means transferring a medically processed fecal sample from one person’s gut to another. The thousands of microorganisms contained within the sample have therapeutic benefits. Most of these benefits are still in the research phase. However, healthcare providers do prescribe fecal transplants for recurrent C. diff infections. #thegutpeople #guthealth #gutmicrobiome #probiotics #prebiotics #FMT